Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Yixue Wen"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Globally, breast cancer continues to be the leading cause of cancer-related incidence and mortality among females. Research has shown that sleep patterns significantly influence tumor onset and progression. In this research, the association
Externí odkaz:
https://doaj.org/article/e35056048e7a4babb7885db243d0942d
Autor:
Binwei Lin MM, Jinjia Fan MM, Fang Liu MD, Yixue Wen MM, Jie Li MD, Feng Gao MD, Yu Zhang MD, Gang Feng MM, Xiaobo Du MD, Wenzhi Chen MD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 22 (2023)
Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer. Method: HER2-positive breast cancer from patien
Externí odkaz:
https://doaj.org/article/6155f9c6dea543498514a275594783c3
Autor:
Zhuowei Tang, Yuzhu Ji, Yu Min, Xiaohong Zhang, Weiyun Xu, Lijuan Zhao, Jing Zhang, Li Long, Jing Feng, Yixue Wen
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
BackgroundTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. In the elderly (≥70 years old) primary operable (T1-3N0-1M0) TNBC, individualized treatment modalities for this population are pivotal and important, but limi
Externí odkaz:
https://doaj.org/article/5585502d85ab45a6994af835d19372a3
Autor:
Jie Li, Youling Gong, Peng Diao, Qingmei Huang, Yixue Wen, Binwei Lin, Hongwei Cai, Honggang Tian, Bing He, Lanlan Ji, Ping Guo, Jidong Miao, Xiaobo Du
Publikováno v:
Radiation Oncology, Vol 13, Iss 1, Pp 1-8 (2018)
Abstract Background Some Chinese patients with esophageal squamous cell carcinomaare often treated with single-agent concurrent chemoradiotherapy. However, no results have been reported from randomized controlled clinical trials comparing single-agen
Externí odkaz:
https://doaj.org/article/60b1230bc9424d9d98659021ecc7c0fc
Autor:
Huan Du, Gang Feng, Yu Zhang, Surong Ren, Xiyue Yang, Lidan Geng, Jie Li, Binwei Lin, Li Yuan, Yixue Wen, Miao Xiang, Xiaobo Du
Publikováno v:
The Oncologist
Lessons Learned Background This study aimed to evaluate the efficacy and safety of anlotinib combined with S-1 as a third- or later-line treatment for patients with stage IV non-small cell lung cancer (NSCLC). Anlotinib was approved in 2018 by the Ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0df4f92eaef791306392dd33a1bd8ea7
https://doi.org/10.1002/onco.13950
https://doi.org/10.1002/onco.13950
Autor:
Gang Feng, Yan Gui, Yang Chen, Xiaobo Du, Mingqiang Sun, Honggang Tian, Jidong Miao, Zhenhuan Zhao, Hongwei Cai, Qiang Jia, Min Wei, Yu Zhang, Yixue Wen, Dongbiao Liao
Publikováno v:
The Oncologist
Lessons Learned The efficacy of single-agent chemotherapy was not significantly different from that of double-agent chemotherapy in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma. Single-agent concurrent chemoradiother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf21b755443ecff26f5ca37ad2797e1c
https://doi.org/10.1634/theoncologist.2020-0808
https://doi.org/10.1634/theoncologist.2020-0808
Publikováno v:
Asian Pacific Journal of Cancer Prevention : APJCP
Background A proportion of patients with stage IV non-small-cell lung cancer (NSCLC) is predicted to receive third-line treatment. However, currently no standard third-line treatment for NSCLC is available. Anlotinib is an oral, multi-targeted tyrosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2961943e96cb4186775ea31c96b836e7
https://doi.org/10.31557/apjcp.2019.20.12.3849
https://doi.org/10.31557/apjcp.2019.20.12.3849
Autor:
Jing Zhang, Xiao-Hong Zhang, Li Long, Yuzhu Ji, Zhuowei Tang, Jing Feng, Li-Juan Zhao, Wei-Yun Xu, Yixue Wen
Background: The prognostic impact of tumor location on breast cancer patients is not consistent and still controversial. We aimed to investigate the prognostic role of primary tumor location on the survival of patients with breast cancer. Methods: Us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a160b3548f4a2a985deab634b8d9adf1
https://doi.org/10.21203/rs.3.rs-284601/v1
https://doi.org/10.21203/rs.3.rs-284601/v1
Autor:
Gang Feng, Lidan Geng, Xiaobo Du, Tangzhi Dai, Huan Du, Xiyue Yang, Zhongzheng Xiang, Lei Liu, Jie Li, Yixue Wen, Yu Zhang, Jie Bai
Publikováno v:
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 154
BACKGROUND AND PURPOSE This study aimed to evaluate the efficacy of radical radiotherapy and assess prognostic factors in metachronous oligometastatic esophageal cancer (MOEC) patients after initial treatment with curative-intent surgery and/or chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccaadef1946d4d9786de9c1b7c310b6d
https://pubmed.ncbi.nlm.nih.gov/32980382
https://pubmed.ncbi.nlm.nih.gov/32980382
Autor:
Guobo Du, Lei Liu, Hongwei Cai, Tangzhi Dai, Yu Zhang, Zhenhua Zhao, Gang Feng, Xiaobo Du, Dongbiao Liao, Xuhai Zhen, Yixue Wen, Jie Bai, Jie Li, Lidan Geng, Miao Xiang, Xiyue Yang
Publikováno v:
Medicine
Introduction: Re-irradiation after radiotherapy is a common treatment for locally recurrent esophageal cancer. However, the side effects of re-irradiation are serious. The most serious adverse reactions of re-irradiation include esophageal perforatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5fe24f35e02e6141c8c4574e820145e
https://pubmed.ncbi.nlm.nih.gov/31261551
https://pubmed.ncbi.nlm.nih.gov/31261551